Furthermore, NSCLC patients with ALK gene rearrangement and EGFR mutations are more likely to have liver metastasis compared to patients without ALK gene rearrangement, EGFR mutation, and KRAS mutation [22]. This evidence concerns the gene ALK and non-small cell lung carcinoma.